Table 1 Clinical data and outcomes of metastatic gastric cancer patients in terms of resectability
From: Palliative gastrectomy is beneficial in selected cases of metastatic gastric cancer
Parameters | Resection (n = 193) | Non-resection (n = 140) | P value |
|---|---|---|---|
Age (years), median (range) | 65 (26–89) | 63 (22–91) | 0.782 |
Gender | 0.393 | ||
Male | 126 (65.3) | 85 (60.7) | |
Female | 67 (34.7) | 55 (39.3) | |
Platelet (103/uL), median (range) | 258.5 (58–680) | 281 (73–622) | 0.609 |
Hemoglobin (g/dL), median (range) | 10.9 (3.8–20.6) | 11.0 (4.0–16.5) | 0.881 |
Albumin (g/dL), median (range) | 3.7 (1.7–4.9) | 3.7 (1.9–4.9) | 0.135 |
AST (U/L), median (range) | 18 (5–223) | 19 (4–340) | 0.491 |
ALT (U/L), median (range) | 14 (1–156) | 14 (2–106) | 0.975 |
ALK-P (U/L), median (range) | 67 (20–349) | 64 (30–459) | 0.998 |
Total bilirubin, (mg/dL) (range) | 0.6 (0.2–1.8) | 0.6 (0.2–2.0) | 0.252 |
Creatinine (mg/dL), median (range) | 0.9 (0.3–11.2) | 1.0 (0.4–3.4) | 0.500 |
Charlson comorbidity index score | 0.529 | ||
2 | 89 (46.1) | 74 (52.9) | |
3 | 71 (36.8) | 47 (33.6) | |
4 | 21 (10.9) | 10 (7.1) | |
≥ 5 | 12 (6.2) | 9 (6.4) | |
Tumor-associated symptoms | 110 (57.0) | 82 (58.6) | 0.774 |
Metastatic pattern | 0.029 | ||
Hematogenous spread alone | 56 (29.0) | 26 (18.6) | |
Peritoneum | 137 (71.0) | 114 (81.4) | |
Complications | 36 (18.7) | 28 (20.0) | 0.758 |
In-hospital mortality | 20 (10.4) | 13 (9.3) | 0.745 |
Mortality within 1 month | 14 (7.3) | 6 (4.3) | 0.260 |
Chemotherapy | 124 (64.2) | 83 (59.3) | 0.357 |
Survival time (months) | 0.005 | ||
≤ 6 | 82 (42.5) | 81 (57.9) | |
6 ~ 12 | 54 (28.0) | 37 (26.4) | |
> 12 | 57 (29.5) | 22 (15.7) |